Obesity Management: Optimizing Care of Your Patients - Webcast

The webcast activity Obesity Management: Optimizing Care of Your Patients was originally presented at Clinical Endocrinology Update 2016 in Seattle, Washington on September 8, 2016.

Expert faculty discussed managing patients with obesity.

This activity is supported by an educational grant from Novo Nordisk Inc. and Ethicon Endo-Surgery, Inc.

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists and endocrine fellows, pediatric endocrinologist and pediatric fellows and healthcare professionals who treat patients with obesity.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Recognize the behavioral approaches to obesity management that are most impactful in practice
  • Describe the mechanism of action, safety, and efficacy of new medical therapies for obesity
  • Develop an approach to choosing a treatment strategy that is most optimal for managing obesity
  • Explain the comparative effectiveness of the surgical treatments for obesity, including what is known about mechanisms of action

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Quality Improvement and Healthcare Delivery
General Endocrinology
Obesity
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
09/09/2016
Course expires: 
09/30/2017
Rating: 
0
Seattle, WA
United States

Ken Fujioka, MD
Physician
Scripps
La Jolla, CA

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Ken Fujioka, MD: Research Support, Novo Nordisk; Consultant, Eisai, Gelesis, KVK-tech, Novo Nordisk, Orexigen; Speaker, Novo Nordisk, Orexigen, Takeda

The following SPC member who planned and reviewed content for this activity reported no financial relationships: Connie Newman, MD

The following SPC Committee members reported financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, DexCom, Lexicon Medtronic, Novo Nordisk, Sanofi Aventis; Consultant, Novo Nordisk, Eli Lilly, Janssen, Dexcom
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
E Michael Lewiecki, MD: Advisory Board, Amgen, Merck, Eli Lilly, Radius Health, Shire, and Alexion; Speaker, Shire; Research Grant Support, Amgen, Eli Lilly, Merck
Alan Kelly, MD: Research Support, Novo Nordisk; Speaker, Novo Nordisk, Boehringer Ingelheim
Lisa Nachtigall, MD: Consultant, Pfizer, Chiasma
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim, Pfizer

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships: Giuseppe Barbesino, MD; Natalie Cusano, MD; Joan Han, MD; Amy Rothberg, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation

Accreditation Period

Course opens: 
09/09/2016
Course expires: 
09/30/2017